Harmony Biosciences saw the highest growth of 2.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Harmony Biosciences’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Harmony Biosciences has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 38% of filings. The United States(US), European Patent Office(EPO), Australia(AU), and Brazil(BR) patent Office are among the top ten patent offices where Harmony Biosciences is filings its patents. Among the top granted patent authorities, Harmony Biosciences has 100% of its grants in European Patent Office(EPO).
AbbVie could be the strongest competitor for Harmony Biosciences
Patents related to rare diseases lead Harmony Biosciences's portfolio
Harmony Biosciences has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Epilepsy related patents lead Harmony Biosciences portfolio followed by pain, and fragile x syndrome
Harmony Biosciences has highest number of patents in epilepsy followed by pain, fragile x syndrome.
For comprehensive analysis of Harmony Biosciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

